Literature DB >> 12974761

Reconstitution of CD4+ T cell responses in HIV-1 infected individuals initiating highly active antiretroviral therapy (HAART) is associated with renewed interleukin-2 production and responsiveness.

G A D Hardy1, N Imami, A K Sullivan, A Pires, C T Burton, M R Nelson, B G Gazzard, F M Gotch.   

Abstract

Reconstitution of functional CD4(+) T cell responsiveness to in vitro stimuli is associated with continuous highly active antiretroviral therapy (HAART). Thirty-six antiretroviral naive patients received HAART over 16 weeks. Antigen-specific, mitogen and interleukin (IL)-2 induced lymphocyte proliferative responses and specific IL-2 and IL-4 production were assessed at each time-point, together with quantification of HIV-1 RNA load and lymphocyte populations. Reconstitution of recall responses was limited largely to persistent antigens such as Herpes simplex virus and Candida, rather than to HIV-1 or neo-antigens. Recall antigens, mitogens and IL-2-induced renewed responses were associated with in-vitro production of IL-2, but not IL-4. Differential responsiveness to low versus high concentration IL-2 stimulus increases in a stepwise manner, suggesting normalization of IL-2 receptor expression and improved functionality. These increases in in-vitro proliferative responses thus probably reflect short lived effector clones, driven by ongoing antigenic stimulus associated with persisting long-term organisms. In this context non-responsiveness to HIV-1 antigens suggests ongoing HIV-1 specific clonal T cell anergy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12974761      PMCID: PMC1808838          DOI: 10.1046/j.1365-2249.2003.02256.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

1.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

Review 2.  The Th1/Th2 paradigm.

Authors:  S Romagnani
Journal:  Immunol Today       Date:  1997-06

3.  Decay characteristics of HIV-1-infected compartments during combination therapy.

Authors:  A S Perelson; P Essunger; Y Cao; M Vesanen; A Hurley; K Saksela; M Markowitz; D D Ho
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

4.  HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies.

Authors:  M Connors; J A Kovacs; S Krevat; J C Gea-Banacloche; M C Sneller; M Flanigan; J A Metcalf; R E Walker; J Falloon; M Baseler; I Feuerstein; H Masur; H C Lane
Journal:  Nat Med       Date:  1997-05       Impact factor: 53.440

5.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

Authors:  E S Rosenberg; J M Billingsley; A M Caliendo; S L Boswell; P E Sax; S A Kalams; B D Walker
Journal:  Science       Date:  1997-11-21       Impact factor: 47.728

6.  Detection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination.

Authors:  S J Kent; S L Hu; L Corey; W R Morton; P D Greenberg
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques.

Authors:  A Gallimore; M Cranage; N Cook; N Almond; J Bootman; E Rud; P Silvera; M Dennis; T Corcoran; J Stott
Journal:  Nat Med       Date:  1995-11       Impact factor: 53.440

8.  Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.

Authors:  A D Kelleher; A Carr; J Zaunders; D A Cooper
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

9.  Long-term HIV-1 infection without immunologic progression.

Authors:  S P Buchbinder; M H Katz; N A Hessol; P M O'Malley; S D Holmberg
Journal:  AIDS       Date:  1994-08       Impact factor: 4.177

10.  Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.

Authors:  M R Klein; C A van Baalen; A M Holwerda; S R Kerkhof Garde; R J Bende; I P Keet; J K Eeftinck-Schattenkerk; A D Osterhaus; H Schuitemaker; F Miedema
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

View more
  13 in total

1.  Th1/Th2 cytokine profile in patients coinfected with HIV and Leishmania in Brazil.

Authors:  Maria Zilma Andrade Rodrigues; Maria Fernanda Rios Grassi; Sanjay Mehta; Xing-Quan Zhang; Luana Leandro Gois; Robert T Schooley; Roberto Badaro
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

2.  Successful treatment of cerebral vasculitis in an HIV-positive patient with anti-CD25 treatment.

Authors:  C M G Nieuwhof; J Damoiseaux; J W Cohen Tervaert
Journal:  Ann Rheum Dis       Date:  2006-12       Impact factor: 19.103

3.  Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study.

Authors:  Cissy Kityo; Stephanie Bousheri; Juliette Akao; Francis Ssali; Rose Byaruhanga; Isaac Ssewanyana; Prossy Muloma; Sula Myalo; Rose Magala; Yichen Lu; Peter Mugyenyi; Huyen Cao
Journal:  Vaccine       Date:  2011-01-04       Impact factor: 3.641

4.  Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudy.

Authors:  C T Burton; R L Goodall; A Samri; B Autran; A D Kelleher; G Poli; G Pantaleo; F M Gotch; N Imami
Journal:  Clin Exp Immunol       Date:  2008-05       Impact factor: 4.330

5.  Role of CD8(+) T cells in triggering reversal reaction in HIV/leprosy patients.

Authors:  Ariane Leite de Oliveira; Thaís Porto Amadeu; Andressa Cristina de França Gomes; Vinícius Martins Menezes; José Augusto da Costa Nery; Roberta Olmo Pinheiro; Euzenir Nunes Sarno
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

6.  Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy.

Authors:  A Pires; M Nelson; A L Pozniak; M Fisher; B Gazzard; F Gotch; N Imami
Journal:  J Immune Based Ther Vaccines       Date:  2005-09-25

7.  Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses.

Authors:  Nesrina Imami; Samantha J Westrop; Nathali Grageda; Anna A Herasimtschuk
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

8.  Loss of Preexisting Immunological Memory Among Human Immunodeficiency Virus-Infected Women Despite Immune Reconstitution With Antiretroviral Therapy.

Authors:  Archana Thomas; Erika Hammarlund; Lina Gao; Susan Holman; Katherine G Michel; Marshall Glesby; Maria C Villacres; Elizabeth T Golub; Nadia R Roan; Audrey L French; Michael H Augenbraun; Mark K Slifka
Journal:  J Infect Dis       Date:  2020-06-29       Impact factor: 7.759

9.  Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up.

Authors:  Anna A Herasimtschuk; Samantha J Westrop; Graeme J Moyle; Jocelyn S Downey; Nesrina Imami
Journal:  J Immune Based Ther Vaccines       Date:  2008-10-31

10.  A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy.

Authors:  Gareth Ad Hardy; Nesrina Imami; Mark R Nelson; Ann K Sullivan; Ron Moss; Marlén Mi Aasa-Chapman; Brian Gazzard; Frances M Gotch
Journal:  J Immune Based Ther Vaccines       Date:  2007-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.